Capricor Therapeutics, Inc. (NasdaqGS: CAPR)
Health Care · Biotechnology · US
$6.61
-0.60% today · +3.3% 1Y
Capricor Therapeutics, Inc. (NasdaqGS: CAPR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $384.30M and employs 231 people.
Over the last twelve months the share price has gained 3.3%, trading between 2.96 and 40.37.
Tweenvest scores Capricor Therapeutics, Inc. across four factors: quality 37/100, value 35/100. Its strongest factor is quality.
CAPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $384.30M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.47
- Dividend yield
- —
- Beta (5Y)
- 0.61
- 52-week high
- $40.37
- 52-week low
- $2.96
- Avg volume (3M)
- —
- Shares outstanding
- 58.14M
- Employees
- 231
- Next earnings
- —
About Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.
- ISIN
- US14070B3096
- Founded
- 2005
- Listed since
- Feb 13, 2007
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Heartseed Inc.TSE: 219A | $390.78M | ¥2,695.00 | +2.04% |
| C4 Therapeutics, Inc.NasdaqGS: CCCC | $388.76M | $3.16 | +9.34% |
| Yantai Zhenghai Biotechnology Co., Ltd.SZSE: 300653 | $388.03M | CN¥14.57 | +1.11% |
| Beijing Luzhu Biotechnology Co., Ltd.SEHK: 2480 | $387.80M | HK$15.30 | +1.93% |
| Guangdong VTR Bio-Tech Co., Ltd.SZSE: 300381 | $383.93M | CN¥5.35 | -5.64% |
| Myriad Genetics, Inc.NasdaqGS: MYGN | $380.69M | $3.98 | -7.66% |
| Rezolute, Inc.NasdaqCM: RZLT | $375.53M | $3.58 | -26.49% |
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $372.92M | $6.03 | +3.43% |
Figures last refreshed Oct 18, 2026.